STOCK TITAN

Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Checkpoint Therapeutics, Inc. will participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference where James Oliviero, President and CEO, will have a fireside chat. The event will take place on May 20, 2024, at 12:30 p.m. ET at NASDAQ. Checkpoint will also have one-on-one meetings during the conference. A webcast of the fireside chat will be available on the News & Events page of Checkpoint's website for 30 days post-event.

Positive
  • None.
Negative
  • None.

WALTHAM, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ, taking place on Monday, May 20, 2024, at 12:30 p.m. ET. Checkpoint will also attend in-person one-on-one meetings during the conference.

A webcast of the fireside chat will be available on the News & Events page, located within the Investors section of Checkpoint’s website, https://ir.checkpointtx.com/event-calendar/default.aspx, for approximately 30 days after the meeting.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc. is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. Checkpoint is evaluating its lead antibody product candidate, cosibelimab, a potential best-in-class anti-PD-L1 antibody licensed from the Dana-Farber Cancer Institute, as a potential new treatment for patients with selected recurrent or metastatic cancers, including metastatic and locally advanced cSCC. Checkpoint is also evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib (formerly CK-101), a third-generation epidermal growth factor receptor (“EGFR”) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer. Checkpoint is headquartered in Waltham, MA and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). For more information, visit www.checkpointtx.com.

Company Contact:
Jaclyn Jaffe
Checkpoint Therapeutics, Inc.
(781) 652-4500
ir@checkpointtx.com

Investor Relations Contact:
Ashley R. Robinson
Managing Director, LifeSci Advisors, LLC
(617) 430-7577
arr@lifesciadvisors.com  

Media Relations Contact:
Katie Kennedy
Gregory FCA
610-731-1045
Checkpoint@gregoryfca.com


FAQ

When will Checkpoint Therapeutics participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference?

Checkpoint Therapeutics will participate on Monday, May 20, 2024, at 12:30 p.m. ET.

Who will be representing Checkpoint Therapeutics at the conference?

James Oliviero, the President and Chief Executive Officer, will participate in a fireside chat.

Where can I watch the webcast of the fireside chat?

The webcast will be available on the News & Events page of Checkpoint's website for approximately 30 days post-event.

Fortress Biotech, Inc.

NASDAQ:FBIO

FBIO Rankings

FBIO Latest News

FBIO Stock Data

51.71M
27.56M
21.21%
13.33%
9.33%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BAY HARBOR ISLANDS